Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Purple Biotech Ltd ADR (NQ: PPBT )

2.530 -0.010 (-0.39%)
Streaming Delayed Price Updated: 10:25 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Purple Biotech Ltd ADR

< Previous 1 2 Next >
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Fortifies NT219 Patent Protection
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces $5 Million Registered Direct Offering
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Debuts Scientific Advisory Board
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
From Purple Biotech Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.